Scientists have found a surprising new way to make certain cancer drugs work dramatically better – by helping them get inside ...

Isomorphic Labs raised $600 million in its first external funding round, led by Thrive Capital with participation from GV and Alphabet, according to the Financial Times. The AI-first drug design and ...

In the current study, the researchers used what is known as fragment-based drug design instead. The method involves first ...

Presently departmental laboratories are devoted toward drug design, synthesis, and characterization. Additionally there is also a strong effort placed in protein receptor characterization and protein ...

Researchers in pharma and beyond have historically glommed onto a limited number of disease targets, limiting innovation. AI ...

The company is building what it describes as an AI drug design engine. The software reduces the amount of manual work involved in developing new medicines and thereby speeds up the process.

Isomorphic will use the windfall to fund development of its next-generation artificial intelligence drug design model, the company announced in a March 31 release. The AI biotech is also looking ...

Drug discovery has always been a complex and multi-faceted process that requires the integration of various disciplines such as biology, chemistry, and computer science. Today Artificial Intelligence ...

Ethan Grimes, BS, and Paul Morgan, MD, conduct rational drug design at the newly launched AI Small Molecule Drug Discovery Center at the Icahn School of Medicine at Mount Sinai. As part of Mount Sinai ...

The event, held in the emblematic Casa de Convalescència, was supported by the BBVA Foundation and welcomed 150 international attendees. The conference addressed how advanced AI models and generative ...

The funding will accelerate further development of Isomorphic’s AI drug design engine and support the company’s goal of bringing its discovered drugs to clinical trials. Isomorphic Labs was ...